HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory

Stock News12-08

LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new products have been successfully included in either the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" (National Reimbursement Drug List) or the "Commercial Health Insurance Innovative Drug Directory (2025)" (Commercial Insurance Innovative Drug Directory), both issued by the National Healthcare Security Administration.

The five new products include Mimexin® (oxycodone-naloxone prolonged-release tablets) and Ruibailai® (paliperidone palmitate injection (II)), which were newly added to the National Reimbursement Drug List. Zanbijia® (lurbinectedin for injection) was successfully selected for the Commercial Insurance Innovative Drug Directory. Meanwhile, Baitowei® (goserelin acetate microspheres for injection) and Ruiketuo® (risperidone microspheres for injection (II)) were renewed and continue to be included in the National Reimbursement Drug List.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145915321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145915321","market":"other","top_or_hot":-1,"title":"HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory","media":"Stock News","content":"<p>LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new products have been successfully included in either the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" (National Reimbursement Drug List) or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" (Commercial Insurance Innovative Drug Directory), both issued by the National Healthcare Security Administration.</p>\n<p>The five new products include Mimexin® (oxycodone-naloxone prolonged-release tablets) and Ruibailai® (paliperidone palmitate injection (II)), which were newly added to the National Reimbursement Drug List. Zanbijia® (lurbinectedin for injection) was successfully selected for the Commercial Insurance Innovative Drug Directory. Meanwhile, Baitowei® (goserelin acetate microspheres for injection) and Ruiketuo® (risperidone microspheres for injection (II)) were renewed and continue to be included in the National Reimbursement Drug List.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new products have been successfully included in either the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" (National Reimbursement Drug List) or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" (Commercial Insurance Innovative Drug Directory), both issued by the National Healthcare Security Administration.</p>\n<p>The five new products include Mimexin® (oxycodone-naloxone prolonged-release tablets) and Ruibailai® (paliperidone palmitate injection (II)), which were newly added to the National Reimbursement Drug List. Zanbijia® (lurbinectedin for injection) was successfully selected for the Commercial Insurance Innovative Drug Directory. Meanwhile, Baitowei® (goserelin acetate microspheres for injection) and Ruiketuo® (risperidone microspheres for injection (II)) were renewed and continue to be included in the National Reimbursement Drug List.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1145915321","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145915321","pubTimestamp":1765159030,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1161":"生物科技","BK1606":"中医药概念","BK1574":"生物医药B类股","BK1583":"高瓴概念","06978":"永泰生物-B","02186":"绿叶制药","BK1191":"制药"},"translate_title":"港股动向|绿叶制药(02186)涨近3%米美欣等5款新品®纳入国家报销药品目录或商业保险创新药目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"02186":1},"content_text":"LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new products have been successfully included in either the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" (National Reimbursement Drug List) or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" (Commercial Insurance Innovative Drug Directory), both issued by the National Healthcare Security Administration.\nThe five new products include Mimexin® (oxycodone-naloxone prolonged-release tablets) and Ruibailai® (paliperidone palmitate injection (II)), which were newly added to the National Reimbursement Drug List. Zanbijia® (lurbinectedin for injection) was successfully selected for the Commercial Insurance Innovative Drug Directory. Meanwhile, Baitowei® (goserelin acetate microspheres for injection) and Ruiketuo® (risperidone microspheres for injection (II)) were renewed and continue to be included in the National Reimbursement Drug List.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145915321","isCrawlerRequest":true}